1. Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date;Akamine;Onco. Targets Ther.,2018
2. https://www.uptodate.com/contents/lorlatinib-drug-information?source=history_widget (Last Accessed 7 August 2019).
3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf (Accessed 4 January 2020).
4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf (Accessed 4 January 2020).
5. Acquired resistance to crizotinib from a mutation in CD74-ROS1;Awad;N. Engl. J. Med.,2013